To investigate the efficacy of mirabegron for lower urinary tract symptoms in patients with an indwelling ureteral stent after ureterorenoscopic lithotripsy. This was a prospective follow-up study of 76 patients with stent-related symptoms (SRSs). Patients with upper urinary calculi who were pre-stented for > 2 weeks before lithotripsy were examined for the presence of SRSs by tests including the International Prostate Symptom Score (IPSS), OAB Symptom Score (OABSS), and urinary bother and pain measured by a Visual Analogue Scale (VAS) before lithotripsy. Mirabegron (50 mg/day) was prescribed post-lithotripsy for 2 weeks. SRSs were assessed at the time of stent removal. The IPSS scores improved significantly from 16.2 to 14.3 (p<0.001) and the IPSS-QoL scores decreased significantly from 5.0 to 4.6 (p=0.012). The OABSS scores improved significantly from 7.7 to 6.8 (p=0.006), and the urinary urgency scores (OABSS-Q3) decreased significantly from 3.24 to 2.68 (p<0.001). The number of nocturia episodes decreased significantly from 2.5 to 2.2 (p=0.045). Urinary bother and pain assessed by the VAS declined from 4.2 and 3.1 to 3.8 (p=0.15) and 2.5 (p=0.075), respectively. Mirabegron significantly improved SRSs and the number of nocturia episodes due to a ureteral stent.
Acta medica Okayama. 2020 Apr [Epub]
Hideo Otsuki, Tomoya Yamasaki, Shunsuke Hori, Hiroshi Aoki, Takeo Kosaka, Shinya Uehara, Kei Fujio
Department of Urology, Abiko Toho Hospital, Abiko, Chiba 270-1166, ., Department of Urology, Abiko Toho Hospital, Abiko, Chiba 270-1166, Japan., Department of Urology, Keio University, Shinjuku-ku, Tokyo 160-8582, Japan., Department of Urology, Kawasaki Medical School General Medical Center, Okayama 700-8505, Japan.